Smith Karen L, Jessop David S, Finn David P
Department of Pharmacology and Therapeutics, NCBES Neuroscience Cluster, National University of Ireland, Galway, Ireland.
Stress. 2009 Mar;12(2):97-114. doi: 10.1080/10253890802302908.
In this review, we present evidence for the involvement of imidazoline binding sites (IBS) in modulating responses to stress, through central control of monoaminergic and hypothalamo-pituitary-adrenal (HPA) axis activity. Pharmacological and physiological evidence is presented for differential effects of different IBS subtypes on serotoninergic and catecholaminergic pathways involved in control of basal and stress-stimulated HPA axis activity. IBS ligands can modulate behavioural and neuroendocrine responses in animal models of stress, depression and anxiety, and a body of evidence exists for alterations in central IBS expression in psychiatric patients, which can be normalised partially or fully by treatment with antidepressants. Dysfunction in monoaminergic systems and the HPA axis under basal and stress-induced activation has been extensively reported in psychiatric illnesses. On the basis of the literature, we suggest a potential therapeutic role for selective IBS ligands in the treatment of depression and anxiety disorders.
在本综述中，我们提供证据表明，通过对单胺能和下丘脑 - 垂体 - 肾上腺（HPA）轴活动的中枢控制，咪唑啉结合位点（IBS）参与调节对应激的反应。文中呈现了药理学和生理学证据，证明不同IBS亚型对参与基础和应激刺激的HPA轴活动控制的5-羟色胺能和儿茶酚胺能途径具有不同影响。IBS配体可调节应激、抑郁和焦虑动物模型中的行为和神经内分泌反应，并且有证据表明精神疾病患者中枢IBS表达存在改变，而抗抑郁药治疗可部分或完全使其恢复正常。在精神疾病中，基础状态下以及应激诱导激活时单胺能系统和HPA轴功能障碍已有广泛报道。基于文献，我们提出选择性IBS配体在治疗抑郁和焦虑症方面具有潜在治疗作用。
